GWP.L Regulatory News (GWP)

GW Pharmaceuticals PLC ("GW Pharmaceuticals" or the "Company")

NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS

Porton Down, UK, 5 July 2010: GW Pharmaceuticals (AIM: GWP) hereby provides notification that the Company has today been notified of the following series of share transactions, the result of which is an increase in the beneficial interests of Dr Geoffrey Guy and Dr Stephen Wright.

The wife of Dr Stephen Wright, Research and Development Director, has today purchased 5,000 ordinary shares of 0.1p each at the market price of 110 pence per share. This purchase equates to 0.004% of the issued ordinary share capital.

Dr Geoffrey Guy, a Director and Executive Chairman of the Company, has today exercised an option to acquire 120,000 ordinary shares of 0.1p each, equating to 0.09% of the issued ordinary share capital at an exercise price of 36.2 pence per share. This follows the sale of 50,000 ordinary shares of 0.1p each on 30th June 2010, at the market price of 124 pence; 30,000 ordinary shares of 0.1p each on 2nd July 2010 at the market price of 109.6 pence and the sale of 38,678 ordinary shares of 0.1p each today at the market price of 109 pence per share. The total number of shares sold of 118,678 equates to 0.09% of the issued ordinary share capital.

Following these notifications Dr Guy's beneficial interest has increased to 18,345,274 ordinary shares, amounting to 14.11% of the shares in issue, and Dr Wright's beneficial interest has increased to 5,000 ordinary shares, amounting to 0.004% of the shares in issue.

The total number of shares outstanding in the Company is 130,041,372 ordinary shares of 0.1p each.

For further information, please contact:

GW Pharmaceuticals PLC +44 (0)1980 557 000

Adam George, Company Secretary

Piper Jaffray Ltd (Nominated Adviser)

Neil Mackison/Rupert Winckler +44 (0) 203 142 8700